186 related articles for article (PubMed ID: 14652525)
1. Evidence-based use of colony-stimulating factors in elderly cancer patients.
Lyman GH; Kuderer N; Agboola O; Balducci L
Cancer Control; 2003; 10(6):487-99. PubMed ID: 14652525
[TBL] [Abstract][Full Text] [Related]
2. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
3. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
[TBL] [Abstract][Full Text] [Related]
4. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
[TBL] [Abstract][Full Text] [Related]
5. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.
Lyman GH
J Natl Compr Canc Netw; 2005 Jul; 3(4):557-71. PubMed ID: 16038646
[TBL] [Abstract][Full Text] [Related]
6. Balancing the benefits and costs of colony-stimulating factors: a current perspective.
Lyman GH
Semin Oncol; 2003 Aug; 30(4 Suppl 13):10-7. PubMed ID: 14508715
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of febrile neutropenia.
Lyman GH; Kuderer NM
Support Cancer Ther; 2003 Oct; 1(1):23-35. PubMed ID: 18628128
[TBL] [Abstract][Full Text] [Related]
8. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
[TBL] [Abstract][Full Text] [Related]
9. A predictive model for neutropenia associated with cancer chemotherapy.
Lyman GH
Pharmacotherapy; 2000 Jul; 20(7 Pt 2):104S-111S. PubMed ID: 10905685
[TBL] [Abstract][Full Text] [Related]
10. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.
Lyman GH; Kuderer NM
Crit Rev Oncol Hematol; 2004 May; 50(2):129-46. PubMed ID: 15157662
[TBL] [Abstract][Full Text] [Related]
11. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
Heuser M; Ganser A; Bokemeyer C; ; ;
Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
[TBL] [Abstract][Full Text] [Related]
12. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses.
Kearney N; Friese C
Eur J Oncol Nurs; 2008 Feb; 12(1):14-25. PubMed ID: 18291720
[TBL] [Abstract][Full Text] [Related]
13. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
Smith TJ; Khatcheressian J; Lyman GH; Ozer H; Armitage JO; Balducci L; Bennett CL; Cantor SB; Crawford J; Cross SJ; Demetri G; Desch CE; Pizzo PA; Schiffer CA; Schwartzberg L; Somerfield MR; Somlo G; Wade JC; Wade JL; Winn RJ; Wozniak AJ; Wolff AC
J Clin Oncol; 2006 Jul; 24(19):3187-205. PubMed ID: 16682719
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
15. The colony-stimulating factors: use to prevent and treat neutropenia and its complications.
Komrokji RS; Lyman GH
Expert Opin Biol Ther; 2004 Dec; 4(12):1897-910. PubMed ID: 15571452
[TBL] [Abstract][Full Text] [Related]
16. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
17. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH
Value Health; 2005; 8(1):47-52. PubMed ID: 15841893
[TBL] [Abstract][Full Text] [Related]
18. Myelosuppression and its consequences in elderly patients with cancer.
Balducci L
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):27-32. PubMed ID: 14682116
[TBL] [Abstract][Full Text] [Related]
19. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma.
Chrischilles E; Delgado DJ; Stolshek BS; Lawless G; Fridman M; Carter WB
Cancer Control; 2002; 9(3):203-11. PubMed ID: 12060818
[TBL] [Abstract][Full Text] [Related]
20. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.
Balducci L; Al-Halawani H; Charu V; Tam J; Shahin S; Dreiling L; Ershler WB
Oncologist; 2007 Dec; 12(12):1416-24. PubMed ID: 18165618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]